CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India

Core Insights - CytoSorbents Corporation and Converge Biotech have formed a strategic collaboration to enhance their market presence in the sepsis and critical care sectors in India [1][3] - The partnership aims to leverage CytoSorbents' blood purification technology, CytoSorb®, to improve patient outcomes in critical care settings across India [2][4] Company Overview - CytoSorbents is recognized for its flagship product, CytoSorb®, which is designed to mitigate "cytokine storm" and remove inflammatory toxins, addressing critical illnesses prevalent in India such as sepsis and septic shock [2][5] - CytoSorb is utilized in 76 countries, with over 250,000 treatments administered globally [2][7] - Converge Biotech specializes in critical care and has a robust sales force and hospital network in India, aiming to accelerate the market penetration of CytoSorb [3][5] Strategic Collaboration - The collaboration will enable Converge Biotech to integrate CytoSorb into its existing ICU portfolio, enhancing the treatment options available for life-threatening diseases [3][4] - Both companies anticipate that this partnership will drive growth and improve access to life-saving therapies in one of the fastest-growing critical care markets globally [4][5] Product Applications - CytoSorbents' technology is applicable in various critical conditions, including the removal of blood thinners during surgery and the treatment of severe inflammatory responses in diseases like sepsis and liver failure [5][6] - The product has received regulatory approvals in the European Union and has been granted Emergency Use Authorization by the FDA for use in critically ill COVID-19 patients [7][8]